11/25/2008

Cerus Corp. has commenced a Phase I clinical trial of its INTERCEPT Blood System for red blood cells to evaluate the post-transfusion recovery and lifespan of patients who received transfusions with INTERCEPT-treated red blood cells compared with patients who received transfusions with untreated red blood cells. The trial is expected to conclude in the second quarter of 2009.

Full Story:
RTT News

Related Summaries